San Antonio Scientists Fast-Track Cancer Treatments to Patients

In San Antonio, the distance between a cancer breakthrough and a patient's bedside has never been shorter.

Scientists at The University of Texas at San Antonio work just buildings away from doctors treating patients at UT Health San Antonio's Mays Cancer Center. That physical closeness creates something powerful: discoveries made in the lab on Monday can shape treatment decisions for patients by Friday.

This tight partnership is delivering real results. Researchers recently cracked why certain breast, ovarian, and prostate cancer treatments stop working in some patients, publishing their findings in Science, one of the world's top journals. Those insights are already helping doctors design better treatment plans.

The university also leads the nation's only research program focused on APOBEC, a biological process that causes cancer to mutate and return. The $10 million project aims to stop this process in its tracks, preventing cancer from coming back.

But discovery alone doesn't save lives. That's where the integration matters most.

At the UT Health San Antonio Multispecialty and Research Hospital, doctors can offer patients access to cutting-edge treatments through clinical trials before they're widely available. The hospital recently treated its first inpatient clinical trial participant, adding to more than 500 active trials across the system.

One promising example: an experimental nanotherapy for glioblastoma, one of the deadliest brain cancers. Developed in a UT San Antonio lab, early results show it could significantly extend survival for patients whose cancer has returned.

The Ripple Effect

This integrated approach is changing cancer care across South Texas, a region where cancer rates continue climbing. Patients who might have traveled hundreds of miles for specialized treatment can now access the latest therapies close to home.

The impact extends beyond today's patients. Medical students, residents, and fellows train alongside physician-scientists, learning to bridge the gap between research and care. They're preparing to lead the next wave of cancer innovation.

Dr. Lei Zheng, executive director at Mays Cancer Center, explains the advantage simply: "When research and patient care are integrated, we can translate discoveries into real treatment options much faster."

The model also attracts top scientific talent. Dr. Daohong Zhou, who co-directs the Center for Innovative Drug Discovery, brings together experts from biomedical sciences, engineering, data science, and population health to identify new ways to attack cancer.

As cancer becomes more complex, this team approach grows more essential. One discovery about why a therapy fails can spark five new ideas for better treatments.

For patients in South Texas, that means hope arrives faster than ever before.